RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Ironwood Pharmaceuticals - Stock

Ironwood Pharmaceuticals Stocks 2024

Ironwood Pharmaceuticals Stocks

155.44 M

Ticker

IRWD

ISIN

US46333X1081

WKN

A0X789

In 2024, Ironwood Pharmaceuticals had 155.44 M outstanding stocks, a 0% change from the 155.44 M stocks in the previous year.

The Ironwood Pharmaceuticals Stocks history

YEARNUMBER OF STOCKS (undefined USD)
2029e155.44
2028e155.44
2027e155.44
2026e155.44
2025e155.44
2024e155.44
2023155.44
2022186.31
2021164.42
2020160.7
2019156
2018152.6
2017149
2016144.9
2015142.2
2014136.8
2013115.9
2012106.4
201199.9
201089.7
20097.1
20086.9
20076.7
20066.4

Ironwood Pharmaceuticals shares outstanding

The number of shares was Ironwood Pharmaceuticals in 2023 — This indicates how many shares 155.435 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Ironwood Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Ironwood Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Ironwood Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Ironwood Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Ironwood Pharmaceuticals Aktienanalyse

What does Ironwood Pharmaceuticals do?

Ironwood Pharmaceuticals Inc is a biopharmaceutical company that was founded in 1998. It is headquartered in Cambridge, Massachusetts in the USA. The company develops and markets drugs for the treatment of gastrointestinal diseases and other serious conditions. Ironwood Pharmaceuticals has a diversified product portfolio and works with other pharmaceutical companies to develop innovative therapies. The company's business model is based on the discovery, development, and marketing of drugs for the treatment of gastrointestinal diseases and other serious conditions. Ironwood Pharmaceuticals focuses on the development of new proprietary molecules tailored to specific patient needs. By collaborating with other pharmaceutical companies, Ironwood Pharmaceuticals aims to shorten development time and achieve higher efficiency in the value chain. The different divisions of Ironwood Pharmaceuticals specialize in the development of drugs for various diseases. The company has a strong expertise in the development of drugs for the treatment of gastrointestinal diseases such as irritable bowel syndrome and hyperactive bladder syndrome. Ironwood Pharmaceuticals has also contributed to the research of new therapies for serious conditions such as volvulus and adrenocortical carcinoma. The company has launched several products. The most significant drug of Ironwood Pharmaceuticals is Linzess, a medication for the treatment of chronic constipation and irritable bowel syndrome. The drug increases fluid content in the intestines, facilitating bowel movements. Linzess has proven to be very successful for the company and is available on the market in the USA and other countries. Another important product of Ironwood Pharmaceuticals is Amitiza, a medication for the treatment of chronic constipation in women. The drug increases fluid content in the intestines and stimulates bowel movements. Amitiza has also successfully reached the Japanese market and is available in several countries. Ironwood Pharmaceuticals has also achieved success in other areas of drug development. The company has partnered with Allergan Inc. for the development of drugs against hyperactive bladder syndrome and irritable bowel syndrome. This collaboration has led to new innovative therapies. In general, Ironwood Pharmaceuticals values the needs of patients and works with patient organizations to advance the development of drugs for the treatment of gastrointestinal diseases and other serious conditions. The company is committed to being increasingly concerned about the well-being of patients and the protection of their health. In summary, Ironwood Pharmaceuticals Inc is a leading biopharmaceutical company specializing in the discovery, development, and marketing of drugs for the treatment of gastrointestinal diseases and other serious conditions. With a broad portfolio of innovative therapies and partnerships with other pharmaceutical companies, Ironwood Pharmaceuticals contributes to improving the lives of patients worldwide. Ironwood Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Ironwood Pharmaceuticals's Shares Outstanding

Ironwood Pharmaceuticals's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Ironwood Pharmaceuticals’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Ironwood Pharmaceuticals’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Ironwood Pharmaceuticals’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Ironwood Pharmaceuticals Stock

How many stocks are there of Ironwood Pharmaceuticals?

The current number of stocks of Ironwood Pharmaceuticals is 155.44 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Ironwood Pharmaceuticals are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Ironwood Pharmaceuticals evolved in recent years?

The number of shares of Ironwood Pharmaceuticals has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Ironwood Pharmaceuticals as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Ironwood Pharmaceuticals?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Ironwood Pharmaceuticals pay?

Over the past 12 months, Ironwood Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Ironwood Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Ironwood Pharmaceuticals?

The current dividend yield of Ironwood Pharmaceuticals is .

When does Ironwood Pharmaceuticals pay dividends?

Ironwood Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Ironwood Pharmaceuticals?

Ironwood Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Ironwood Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Ironwood Pharmaceuticals located?

Ironwood Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Ironwood Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Ironwood Pharmaceuticals from 6/30/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/30/2024.

When did Ironwood Pharmaceuticals pay the last dividend?

The last dividend was paid out on 6/30/2024.

What was the dividend of Ironwood Pharmaceuticals in the year 2023?

In the year 2023, Ironwood Pharmaceuticals distributed 0 USD as dividends.

In which currency does Ironwood Pharmaceuticals pay out the dividend?

The dividends of Ironwood Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Ironwood Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Ironwood Pharmaceuticals

Our stock analysis for Ironwood Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Ironwood Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.